Premium
Cell‐permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis
Author(s) -
Petri Susanne,
Kiaei Mahmoud,
Damiano Maria,
Hiller Andrew,
Wille Elizabeth,
Manfredi Giovanni,
Calingasan Noel Y.,
Szeto Hazel H.,
Beal M. Flint
Publication year - 2006
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.2006.04018.x
Subject(s) - sod1 , oxidative stress , amyotrophic lateral sclerosis , reactive oxygen species , programmed cell death , superoxide dismutase , apoptosis , mitochondrial respiratory chain , sod2 , neuroprotection , microbiology and biotechnology , mitochondrion , immunostaining , pharmacology , chemistry , biology , medicine , biochemistry , pathology , immunology , immunohistochemistry , disease
Reactive oxygen species (ROS) play a major role in the pathogenesis of neurodegenerative diseases. They are important contributors to necrotic and apoptotic cell death. A major proportion of cellular ROS is generated at the inner mitochondrial membrane by the respiratory chain. In the present study, we investigated a novel peptide antioxidant (SS‐31) targeted to the inner mitochondrial membrane for its therapeutic effects both in vitro and in vivo in the G93A mouse model of amyotrophic lateral sclerosis (ALS). SS‐31 protected against cell death induced by hydrogen peroxide in vitro in neuronal cells stably transfected with either wild‐type or mutant Cu/Zn superoxide dismutase (SOD1). Daily intraperitoneal injections of SS‐31 (5 mg/kg), starting at 30 days of age, led to a significant improvement in survival and motor performance. In comparison with vehicle‐treated G93A mice, SS‐31‐treated mice showed a decreased cell loss and a decrease in immunostaining for markers of oxidative stress in the lumbar spinal cord. This further enhances the concept that pharmacological modification of oxidative stress is a therapeutic option for the treatment of ALS.